The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | What influence do circulating myeloma plasma cells have on the treatment of multiple myeloma?
Bruno Paiva, PhD from the University of Navarra, Pamplona, Spain outlines the three key reasons why myeloma plasma cells circulating in peripheral blood will have a critical influence on the treatment of multiple myeloma (MM) patients. The first is that they are an important biomarker to predict clinical outcome. The second is the ability to measure a patient’s quality of life, and the third is the ability for practitioners to learn about the efficacy of treatment. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
